From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
Code | Company/Research Team | Target | Structure | IgG subclass | Format |
---|---|---|---|---|---|
NI-1701 (TG-1801)a | LightChain bioscience/TG Therapeutics | CD47 × CD19 | Fab+Fab with Fc, 1 + 1, κλ | IgG1 | one antibody arm (kappa) specific for CD47 and a second arm (lambda) specific to CD19, mesothelin or tumor associated antigen |
IMM-0306a | ImmuneOnco Biopharma | CD47 × CD20 | ligand+Fab with Fc, 2 + 2 | IgG1 | SIRPα V2-D1 infused with amino terminal of heavy chain of Rituximab |
DVD-Ig SL/LL | Ravindra Majeti’s lab in Stanford University | CD47 × CD20 | DVD-IgG | IgG1 | The amino terminus of each B6H12 variable domain infused to the carboxyl terminus of each 2B8 with linker”TVAAP” |
SIRPa-gamma-CD20 HC | CD47 × CD20 | ligand+IgG | IgG1 | ligand located in Fab domain of intact aCD20 antibody(2B8, Rituximab) | |
CD20-2GL-SIRPa HC; CD20-4GL-SIRPa HC | CD47 × CD20 | ligand+IgG | IgG1 | ligand located in Fc domain of intact aCD20 antibody(2B8, Rituximab) | |
bi-scFv RTX-CD47 | Wijnand Helfrich’s lab in Wijnand Helfrich | CD47 × CD20 | ScFV+ScFv,1 + 1 | NA | CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv |
LQ007 | Novamab | CD47 × CD20 | nanobody (C terminal) + IgG | IgG4 | nanobody from camel was fused to the carboxyl terminus of Rituximab |
HMBD-004A | Hummingbird bioscience | CD47 × CD33 | Fab+Fab with Fc, 1 + 1 | IgG1 | Humanized anti-CD47 variable domain as an effector arm and the gemtuzumab variable domain as an anti-CD33 or BCMA specificity arm. |
HMBD-004B | Hummingbird bioscience | CD47 × BCMA | Fab+Fab with Fc, 1 + 1 | IgG1 | |
NI-1801a | Light Chain bioscience (Novimmune SA) | CD47 × MSLN | Fab+Fab with Fc,1 + 1,κλ | IgG1 | one arm target to CD47(kappa) and the other arm target to (lambda) mesothelin or tumor associated antigen |
NI-2401 | Light Chain bioscience (Novimmune SA) | CD47 × TAA | Fab+Fab with Fc,1 + 1,κλ | Not Disclosed | |
NI-2601 | Light Chain bioscience (Novimmune SA) | CD47 × TAA | Fab+Fab with Fc,1 + 1,κλ | Not Disclosed | |
PT-886 | Phanes Therapeutics | CD47 × CLDN18.2 | Fab+Fab with Fc, 1 + 1 | Not Disclosed | Not Disclosed |
PT-796 | Phanes Therapeutics | CD47 × FRα | Fab+Fab with Fc, 1 + 1 | Not Disclosed | Not Disclosed |
PT-217 | Phanes Therapeutics | CD47 × DLL3 | Fab+Fab with Fc, 1 + 1 | Not Disclosed | Not Disclosed |
IMM-26011 | ImmuneOnco Biopharma | CD47 × FLT-3 | ligand+Fab with Fc, 2 + 2 | IgG1 | SIRPa V2-D1 linked |
IMM-2902 | ImmuneOnco Biopharma | CD47 × Her2 | ligand+Fab with Fc,2 + 2 | IgG1 | SIRPa V2-D1 linked through a GS linker to amino terminal of light chain coding sequence of Herceptin (Trastuzumab) |
SG3847 | SUMGEN BIOTECH | CD47 × CD38 | ligand+Fab with Fc, 2 + 2 | IgG1 | SIRPa V1-D1 linked through a GS linker to amino terminal of light chain coding sequence of |
HX-009a | HanX Biopharmaceuticals | CD47 × PD-1 | ligand +Fab with Fc, 2 + 2 | IgG4 | amino terminal of extracellular region ligand (SIRPA V2D1) infused with carboxyl terminus of anti PD1 antibody (HX008) |
IBI-322a | Innovent | CD47 × PD-L1 | Fab+nanobody with Fc,1 + 2 | Not Disclosed | one arm target CD47 (Fab from IBI188), the other target is PDL1 (Bivalent nanobody) |
BH-29XX | Hanmi Pharmaceutical | CD47 × PD-L1 | Fab+Fab with Fc, 1 + 1 | Not Disclosed | Not Disclosed |
? | GenSci | CD47 × PD-L1 | Fab+Fv, KIH, 1 + 1 | Not Disclosed | one arm target CD47 (Fab from GenSci-059), the other target is PDL-1(Fv from GenSci-047) |
PMC-122 | PharmAbcine | CD47 × PD-L1 | Not Disclosed | Not Disclosed | Unknown |
ABP-160 | Abpro Therapeutics | CD47 × PD-L1 | Not Disclosed | IgG1 wt | Unknown |
IMM-2505 | ImmuneOnco Biopharma | CD47 × PD-L1 | ligand+Fab with Fc, 2 + 2 | IgG1 | SIRPa V2-D1 infused with amino terminal of heavy chain of antiPDL-1 antibody (Atezolizumab?) |
TJ-L1C4 | I-MAB Biopharma | CD47 × PD-L1 | Not Disclosed | Not Disclosed | PD-L1 antibody acts as the backbone and is linked with CD47 antibody |
IAB | Sinomab | CD47× PD-L1 | CV1(ALX148) + Fab with Fc | IgG1/IgG4 | variable region of atezolizumab and consensus variant 1 (CV1) monomer |
SL-172154a | Shattuck Labs | CD47× CD40 | ligand+ligand with Fc, 1 + 1 | IgG1 | ECDs of SIRPα and CD 40 L, adjoined by a central domain termed SIRPα-Fc-CD 40 L. |
DSP107 | Kahr Medical | CD47 × 41BB | ligand+ligand with Fc, 1 + 1 | IgG1 | human soluble SIRPα and 4-1BBL |
TJ C4GM | I-MAB Biopharma | CD47 × CSF-2R | IgG + fusion protein | IgG1 or G4 | Human GM-CSF was fused to the heavy chain C terminus of CD47 antibody |
IMM-0207 | ImmuneOnco Biopharma | CD47× VEGF | ligand+receptor with Fc, 2 + 2 | IgG1 | SIRPa V2-D1 linked via an Fc fragment of an Ig to an Ig region of an extracellular domain of VEGFR1D |